Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 8;182(6):1369–1378. doi: 10.1111/bjd.18552

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Design of the BOLT study – Basal Cell Carcinoma Outcomes with LDE225 (sonidegib) Treatment. ^aPatients previously treated with sonidegib or other hedgehog pathway inhibitors were excluded. ^bStratification was based on stage, disease histology for patients with laBCC (nonaggressive vs. aggressive) and geographical region. ^cTreatment was continued until disease progression, unacceptable toxicity, death, study termination or withdrawal of consent. AE, adverse event; BCC, basal cell carcinoma; CR, complete response; DOR, duration of response; laBCC, locally advanced BCC; mBCC, metastatic BCC; mRECIST, modified Response Evaluation Criteria in Solid Tumors; ORR, objective response rate; OS, overall survival; PFS, progression‐free survival; Q8W, every 8 weeks; Q12W, every 12 weeks; TTR, time to tumour response.